Allurion Launches AllurionMeds in the US, Introducing an Innovative AI-Native Compounded GLP-1 Program
AllurionMeds aims to meet an urgent need among patients: Sustaining weight loss over the long term
Introducing Coach Iris, a groundbreaking conversational AI behavioral agent specifically created for weight loss and ongoing maintenance, trained through real-world data collected from over 150,000 patients
This new Compounded GLP-1 program aims not only to empower patients with behavioral changes but also to tackle challenges such as weight regain and other associated side effects
The launch significantly extends Allurion’s reach to cover all 50 states, amplifying the mission to combat obesity while establishing a foundation for future product introductions
Allurion Technologies, Inc. (NYSE: ALUR), a trailblazer in the quest to eliminate obesity, has proudly rolled out AllurionMeds, an innovative solution that merges accessible and cost-effective weight loss medications with the firm’s advanced AI-native platform, showcasing features like Coach Iris, virtual consultations with dieticians, and a state-of-the-art connected smart scale that monitors not just body weight, but also muscle and bone mass.
“Patient feedback has been unequivocal: the objective is to maintain weight loss,” noted Dr. Shantanu Gaur, the visionary founder and CEO of Allurion. “Our tailored platform is designed to help individuals shed pounds and retain their achievements. AllurionMeds prioritizes safety, effectiveness, and crucially, efficiency. Without accessible and affordable weight loss medications coupled with AI-driven behavioral modifications, we are risking financial strain on the US healthcare system.”
The market potential for GLP-1 drugs in the United States is substantial, projected to surpass $100 billion with a user base approaching 30 million by the year 2030. Notably, recent studies reveal a concerning trend: nearly 30% of patients discontinue GLP-1 medications within the first month. At the same time, significant muscle mass loss has been reported. If these challenges go unchecked, combined with monthly costs exceeding $1,300 for treatments, the already escalating obesity crisis will worsen, leading to unsustainable healthcare expenses for millions of Americans.
Program Utilizes AI to Mitigate Common Concerns Associated with GLP-1 Treatments, Including Weight Regain
The AllurionMeds GLP-1 program, powered by Coach Iris, seeks to alleviate prevalent concerns expressed by patients eager to start a GLP-1 journey. Participants will gain access to the Allurion Connected Scale and the dedicated GLP-1 companion app. The scale specifically tracks weight along with muscle and bone mass to ensure a comprehensive understanding of both weight loss and the quality of that loss. Earlier research demonstrates that Allurion’s tools, when used alongside the Allurion Balloon, effectively assist users in losing weight while simultaneously increasing muscle mass, thereby facilitating long-term weight maintenance.
“We are leveraging a decade of experience caring for over 150,000 patients to establish an innovative AI-native platform tailored to resolve challenges faced by GLP-1 users and to deliver an unparalleled experience,” emphasized Dr. Gaur. “Insights from real-world GLP-1 usage pinpoint three core problems: inconsistent adherence to medication and support, loss of muscle and bone mass, and the looming financial burden on the healthcare system. AllurionMeds capitalizes on our existing framework to effectively tackle these challenges through round-the-clock AI coaching, thorough monitoring of weight and body metrics, and the provision of high-quality, affordable compounded semaglutide delivered right to consumers’ homes.”
AllurionMeds Collaborates with FDA-Registered Pharmacies to Offer Safe and Cost-Effective GLP-1 Solutions Nationwide
In conjunction with Coach Iris, patients will access GLP-1 medications sourced from an FDA-registered 503b facility, strictly adhering to Current Good Manufacturing Practice (CGMP) standards. Every batch undergoes thorough testing for sterility, potency, and additional quality measures prior to distribution.
“Prioritizing safety and user convenience was essential to our design process for AllurionMeds,” stated Brian Conyer, Vice President of Digital Health at Allurion. “We meticulously evaluated numerous partners before choosing pharmacies that align with our stringent criteria to deliver an always-on experience through Coach Iris. Looking ahead, we intend to broaden the range of GLP-1 offerings and potentially introduce brand-name options, ensuring that patients have access to a plethora of choices throughout their weight loss journey.”
Additionally, the launch of AllurionMeds has seen the company extend its product availability to all 50 states across the US. Previously, the company had launched the Virtual Care Suite, its B2B AI product, to obesity management clinics in the United States.
“AllurionMeds significantly enhances our footprint in the United States,” Dr. Gaur commented. “The partnerships we forge with patients and healthcare providers in this country have the potential to shape our future product launches, firmly establishing our presence in the world’s largest market for obesity treatments.”
To explore AllurionMeds, please visit https://www.allurionmeds.com/.
About Allurion
Allurion is passionately committed to eradicating obesity. The Allurion Program encompasses a comprehensive weight loss platform featuring the Allurion Gastric Balloon, recognized as the world’s first swallowable, Procedure-less™ intragastric balloon designed for weight loss, alongside access to the Allurion Virtual Care Suite. This suite includes the Allurion Mobile App crafted for consumers, Allurion Insights aimed at healthcare providers featuring the innovative Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers independently from the Allurion Program, allowing for personalized monitoring and management of weight loss therapies tailored to patients’ diverse treatment paths—be it gastric balloon, surgical interventions, medical supervision, or nutritional guidance. Please note that the Allurion Gastric Balloon remains an investigational device within the United States.
For further insights into Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Allurion is a registered trademark of Allurion Technologies, Inc. both in the United States and globally.
Forward-Looking Statements
The market opportunity for GLP-1 drugs in the United States is expanding dramatically. Recent studies outline significant discontinuation rates, emphasizing the need for comprehensive support and adherence strategies. The evolving landscape of obesity treatments necessitates an inclusive approach to address the needs of millions afflicted by this condition.
Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
[email protected]
Investor Contact
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
[email protected]
View source version on businesswire.com:
Thank you for providing information about AllurionMeds and its initiatives in weight loss management. Here’s a concise summary of the key points:
### Overview of AllurionMeds
AllurionMeds offers a tailored platform aimed at assisting individuals with weight loss while promoting long-term success. The platform emphasizes safety, effectiveness, and efficiency, providing accessible and affordable weight loss medications along with AI-driven behavioral modifications.
### Market Potential
– The market for GLP-1 drugs in the U.S. is projected to exceed $100 billion by 2030, with an estimated user base of around 30 million.
– There is a high discontinuation rate of GLP-1 medications, with nearly 30% of patients stopping within the first month.
– The rising costs (over $1,300 monthly) and challenges related to muscle mass loss may exacerbate the obesity crisis and healthcare expenses.
### AI Integration
The AllurionMeds program, powered by AI, particularly Coach Iris, addresses common concerns among GLP-1 users, such as:
– Medication adherence
– Muscle and bone mass preservation
– Financial implications for users and the healthcare system
Participants receive access to the **Allurion Connected Scale** and a **GLP-1 companion app**, enabling comprehensive tracking of weight and body metrics, which are crucial for effective weight loss and maintenance.
### Collaboration with FDA-Registered Pharmacies
AllurionMeds collaborates with FDA-registered pharmacies to ensure that their GLP-1 medications are safe and effective, adhering to strict manufacturing standards.
### Expansion and Future Growth
– AllurionMeds recently expanded its product availability to all 50 states in the U.S.
– The company aims to broaden its range of GLP-1 offerings and potentially include brand-name options to enhance patient choice and accessibility.
### About Allurion
Allurion is dedicated to eliminating obesity through various innovative programs, including the **Allurion Gastric Balloon**, a unique swallowable device, along with a comprehensive Virtual Care Suite designed for both patients and healthcare providers.
For more information or to explore AllurionMeds, visit [AllurionMeds Website](https://www.allurionmeds.com/).
If you have specific questions or need further details, feel free to ask!
